PriceTargets.com logo

Context Therapeutics - CNTX Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $6.17
  • Forecasted Upside: 1,592.28%
  • Number of Analysts: 10
  • Breakdown:
  • 1 Sell Ratings
  • 1 Hold Ratings
  • 8 Buy Ratings
  • 0 Strong Buy Ratings
$0.36 As of 09/15/2026 05:00 PM ET
▲ +0.0134 (3.82%)

This chart shows the closing price for CNTX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Context Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CNTX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CNTX

Analyst Price Target is $6.17
▲ +1,592.28% Upside Potential
This price target is based on 10 analysts offering 12 month price targets for Context Therapeutics in the last 3 months. The average price target is $6.17, with a high forecast of $9.00 and a low forecast of $4.00. The average price target represents a 1,592.28% upside from the last price of $0.36.

This chart shows the closing price for CNTX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 10 polled investment analysts is to moderate buy stock in Context Therapeutics. This rating has held steady since September 2025, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 1 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/24/2025
  • 1 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/22/2025
  • 1 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/20/2025
  • 1 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
12/19/2025
  • 1 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
3/19/2026
  • 1 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
6/17/2026
  • 0 strong buy ratings
  • 8 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
8/16/2026
  • 0 strong buy ratings
  • 8 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
9/15/2026

Latest Recommendations

  • 0 strong buy ratings
  • 8 buy ratings
  • 1 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
9/3/2026Weiss RatingsDowngradeSell (D-) ➝ Sell (E+)
8/20/2026Weiss RatingsUpgradeSell (E+) ➝ Sell (D-)
8/6/2026CitigroupReiterated RatingOutperform ➝ Outperform
8/6/2026Weiss RatingsDowngradeSell (D-) ➝ Sell (E+)
8/6/2026Lifesci CapitalDowngradeStrong-Buy ➝ Hold
7/17/2026Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
6/16/2026Maxim GroupLower TargetBuy ➝ Buy$8.00 ➝ $4.00
4/20/2026Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
3/24/2026D. Boral CapitalReiterated RatingBuy ➝ Buy$9.00
3/24/2026GuggenheimReiterated RatingBuy ➝ Buy$5.00
3/24/2026Piper SandlerBoost TargetOverweight ➝ Overweight$4.00 ➝ $7.00
2/23/2026Lifesci CapitalUpgradeStrong-Buy
1/21/2026Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
12/22/2025JonesTradingInitiated CoverageBuy$7.00
11/6/2025D. Boral CapitalReiterated RatingBuy ➝ Buy$9.00
11/6/2025HC WainwrightBoost TargetBuy ➝ Buy$4.00 ➝ $5.00
10/16/2025D. Boral CapitalReiterated RatingBuy ➝ Buy$9.00
10/8/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
10/2/2025Cantor FitzgeraldInitiated CoverageOverweight
9/27/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
9/18/2025GuggenheimInitiated CoverageBuy$5.00
8/7/2025HC WainwrightLower TargetBuy ➝ Buy$5.00 ➝ $4.00
8/7/2025D. Boral CapitalReiterated RatingBuy ➝ Buy$9.00
6/26/2025Piper SandlerReiterated RatingOverweight ➝ Overweight$4.50 ➝ $4.00
5/8/2025D. Boral CapitalReiterated RatingBuy ➝ Buy$9.00 ➝ $9.00
4/29/2025William BlairReiterated RatingOutperform
4/29/2025D. Boral CapitalReiterated RatingBuy ➝ Buy$9.00 ➝ $9.00
4/21/2025William BlairInitiated CoverageOutperform
4/9/2025D. Boral CapitalReiterated RatingBuy ➝ Buy$9.00 ➝ $9.00
3/21/2025D. Boral CapitalReiterated RatingBuy ➝ Buy$9.00 ➝ $9.00
3/21/2025HC WainwrightReiterated RatingBuy ➝ Buy$5.00 ➝ $5.00
1/15/2025D. Boral CapitalReiterated RatingBuy ➝ Buy$9.00 ➝ $9.00
1/8/2025Citizens JmpUpgradeStrong-Buy
1/8/2025Citizens JmpInitiated CoverageOutperform$4.00
11/25/2024D. Boral CapitalInitiated CoverageBuy$9.00
9/23/2024HC WainwrightReiterated RatingBuy ➝ Buy$6.00 ➝ $6.00
9/16/2024HC WainwrightReiterated RatingBuy ➝ Buy$6.00 ➝ $6.00
7/10/2024HC WainwrightReiterated RatingBuy ➝ Buy$5.00 ➝ $5.00
5/16/2024Piper SandlerInitiated CoverageOverweight$4.50
5/9/2024HC WainwrightBoost TargetBuy ➝ Buy$4.00 ➝ $5.00
5/9/2024Maxim GroupBoost TargetBuy ➝ Buy$4.00 ➝ $10.00
3/21/2024HC WainwrightLower TargetBuy ➝ Buy$5.00 ➝ $4.00
11/1/2023HC WainwrightUpgradeNeutral ➝ Buy$5.00
9/11/2023Maxim GroupInitiated CoverageBuy$4.00
3/23/2023HC WainwrightDowngradeBuy ➝ Neutral
2/7/2023HC WainwrightReiterated RatingBuy$4.00
12/8/2022HC WainwrightLower Target$6.00 ➝ $4.00
2/2/2022HC WainwrightInitiated CoverageBuy$6.00
1/24/2022ThinkEquityInitiated CoverageBuy$10.00
(Data available from 9/16/2021 forward)

News Sentiment Rating

-0.16 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
2/18/2026
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/20/2026
  • 2 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/19/2026
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/19/2026
  • 0 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
6/18/2026
  • 0 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/18/2026
  • 0 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
8/17/2026
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 2 very negative mentions
Mentions as of
9/16/2026

Current Sentiment

  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 2 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Context Therapeutics logo
Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.
Read More

Today's Range

Now: $0.36
Low: $0.35
High: $0.38

50 Day Range

MA: $0.51
Low: $0.35
High: $0.69

52 Week Range

Now: $0.36
Low: $0.34
High: $3.62

Volume

1,375,307 shs

Average Volume

1,930,320 shs

Market Capitalization

$33.48 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.69

Frequently Asked Questions

What sell-side analysts currently cover shares of Context Therapeutics?

The following sell-side analysts have issued research reports on Context Therapeutics in the last twelve months: Cantor Fitzgerald, Citigroup Inc., D. Boral Capital, Guggenheim, HC Wainwright, JonesTrading, Lifesci Capital, Maxim Group, Piper Sandler, Wall Street Zen, and Weiss Ratings.
View the latest analyst ratings for CNTX.

What is the current price target for Context Therapeutics?

0 Wall Street analysts have set twelve-month price targets for Context Therapeutics in the last year. Their average twelve-month price target is $6.17, suggesting a possible upside of 1,592.3%. D. Boral Capital has the highest price target set, predicting CNTX will reach $9.00 in the next twelve months. Maxim Group has the lowest price target set, forecasting a price of $4.00 for Context Therapeutics in the next year.
View the latest price targets for CNTX.

What is the current consensus analyst rating for Context Therapeutics?

Context Therapeutics currently has 1 sell rating, 1 hold rating and 8 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for CNTX.

What other companies compete with Context Therapeutics?

Other companies that are similar to Context Therapeutics include Equillium, Oncocyte, TuHURA Biosciences, Biomea Fusion and Corbus Pharmaceuticals. Learn More about companies similar to Context Therapeutics.

How do I contact Context Therapeutics' investor relations team?

Context Therapeutics' physical mailing address is 3675 Market Street, Philadelphia, Pennsylvania 19104. The company's listed phone number is 267-225-7416 and its investor relations email address is [email protected]. The official website for Context Therapeutics is www.contexttherapeutics.com. Learn More about contacing Context Therapeutics investor relations.